GLP‑1 drugs after bariatric surgery produced about 9% weight loss at one year, on weak pooled evidence

Some people regain weight after bariatric surgery, and some never lose as much as expected. A common next step is to add a weight-loss drug. A new review pools what is known about doing that, and the honest summary is that the drugs appear to work while the evidence behind the numbers is thin.

The systematic review and meta-analysis was published in Frontiers in Endocrinology on 26 August 2026. It covers liraglutide, semaglutide and tirzepatide given to adults at least one year after metabolic bariatric surgery who had a poor response to the operation.

The authors screened 2,888 records, narrowed to 2,012 after removing duplicates, and included 27 papers: 3 randomized controlled trials, 22 cohort studies and 2 case series. Nineteen of the 27 went into the pooled numbers.

Pooled weight loss came to about 9% at 12 months for both older drugs

Results are given as percentage of total weight loss, which is the share of starting body weight a person loses. A 250 pound person losing 9% loses about 22 pounds.

For liraglutide, pooled total weight loss was 6.10% at 3 months, 8.34% at 6 months and 9.22% at 12 months.

For semaglutide it was 5.36% at 3 months, 9.34% at 6 months and 9.02% at 12 months.

The confidence ranges are wide enough to change the conclusion

A confidence interval is the range the true value is likely to sit inside. Narrow is good. These are not narrow.

The liraglutide 12-month figure of 9.22% carries a range of 0.83% to 17.60%. The bottom of that range is close to no weight loss at all. The semaglutide 12-month figure of 9.02% runs from 3.43% to 14.62%.

The studies also disagreed with each other heavily. Researchers measure that with a statistic called I squared, where a higher number means more disagreement and anything above 50% is considered substantial. At 12 months it was 98.6% for liraglutide and 95.1% for semaglutide. Values that high mean the pooled average is standing in for results that were not really measuring the same thing.

Some of the shorter timepoints rest on a single study.

The tirzepatide comparison rests on very few patients

Tirzepatide came out ahead of semaglutide by 4.23% of total body weight at 6 months, with a range of 1.42% to 7.05%. At 3 months the difference was 1.69% and the range crossed zero, meaning no clear difference either way.

That comparison draws on a small number of studies, and only one study in the whole review tested tirzepatide on its own. In one of the comparison studies the doses were not matched in strength: semaglutide at 1.25 mg against tirzepatide at 7.5 mg. A dose gap can produce a drug difference by itself, so this is not a fair head to head.

Side effects were common, and mostly the familiar stomach ones

Across seven studies covering 377 people on liraglutide, 39.26% had at least one side effect. Nausea was the most frequent at 23.16%, then constipation at 10.79%, diarrhea and headache at 6.38% each, fatigue at 5.92%, abdominal pain or discomfort at 4.97% and vomiting at 4.00%. For semaglutide, three studies covering 127 people put the figure at 24.41%.

No serious adverse events were reported in the included studies. That is reassuring but it is not proof of safety, because these were mostly small studies that were not designed to pick up rare harms.

The original drug trials excluded people who had surgery

This is why the evidence looks the way it does. The authors point out that previous bariatric surgery was a written exclusion criterion in the large trials that got these drugs approved. Post-surgical patients were deliberately kept out, so nearly everything known about this use comes from smaller academic studies and clinic records gathered afterward.

The authors also flag that studies define a poor response to surgery differently, that they report weight loss in different units, and that publication bias tests and subgroup analyses could not be run because too few studies qualified for each pooled estimate. They note that what happens to weight after someone stops the drug is largely unstudied in this group. They state their findings should be read with caution.

Nothing here tells an individual patient what to do. Whether to add a medication after bariatric surgery is a decision for the surgical and medical team that knows the case.